tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
PremiumRatingsPromising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
2M ago
Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)
Premium
The Fly
Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)
2M ago
Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination
Premium
Company Announcements
Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination
2M ago
Vaxcyte advances VAX-31 infant Phase 2 study
PremiumThe FlyVaxcyte advances VAX-31 infant Phase 2 study
4M ago
Vaxcyte Reports Progress in Vaccine Development
Premium
Company Announcements
Vaxcyte Reports Progress in Vaccine Development
4M ago
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating
Premium
Ratings
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating
5M ago
Vaxcyte vaccine candidates contain aluminum, says Mizuho
PremiumThe FlyVaxcyte vaccine candidates contain aluminum, says Mizuho
6M ago
Vaxcyte Holds Annual Stockholders Meeting on Governance
Premium
Company Announcements
Vaxcyte Holds Annual Stockholders Meeting on Governance
6M ago
FDA head says vaccine framework being prepared
Premium
The Fly
FDA head says vaccine framework being prepared
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100